Nurix Therapeutics (NRIX) Operating Leases (2021 - 2026)

Nurix Therapeutics (NRIX) has 6 years of Operating Leases data on file, last reported at $54.9 million in Q2 2026.

• On a quarterly basis, Operating Leases rose 846.93% year-over-year to $54.9 million in Q2 2026; TTM through May 2026 was $54.9 million, a 846.93% increase from a year earlier, with the FY2025 full-year figure at $52.9 million, up 160.76% from the prior year.
• Operating Leases for Q2 2026 stood at $54.9 million, down from $55.5 million in the prior quarter.
• Over the last five years, Operating Leases for NRIX reached as high as $55.5 million in Q1 2026 and fell as low as $2.6 million in Q3 2023.
• Historically, Operating Leases has averaged $21.9 million across 5 years, with a median of $20.1 million in 2024.
• Across the five-year window, Operating Leases slumped 72.23% in 2025 and jumped 846.93% in 2026, its largest moves.
• Year by year, Operating Leases stood at $6.4 million in 2022, then jumped by 259.42% to $23.1 million in 2023, then fell by 12.26% to $20.3 million in 2024, then jumped by 160.76% to $52.9 million in 2025, then increased by 3.81% to $54.9 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $54.9 million in Q2 2026, $55.5 million in Q1 2026, and $52.9 million in Q4 2025.